As of close of business last night, GlycoMimetics Inc’s stock clocked out at $2.77, down -6.59% from its previous closing price of $2.96. In other words, the price has decreased by -$0.1950 from its previous closing price. On the day, 580691 shares were traded.
Ratios:
To gain a deeper understanding of GLYC’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.41 and its Current Ratio is at 6.41. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, CapitalOne on December 22, 2023, initiated with a Overweight rating and assigned the stock a target price of $12.
On November 12, 2021, Jefferies Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $3 to $4.
On November 14, 2019, ROTH Capital started tracking the stock assigning a Buy rating and target price of $12.ROTH Capital initiated its Buy rating on November 14, 2019, with a $12 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 22 ’23 when Rock Edwin bought 30,403 shares for $1.38 per share. The transaction valued at 41,956 led to the insider holds 375,403 shares of the business.
Rock Edwin bought 35,000 shares of GLYC for $48,300 on Sep 21 ’23. The Chief Medical Officer now owns 345,000 shares after completing the transaction at $1.38 per share. On May 17 ’23, another insider, Hahn Brian M., who serves as the SVP Finance, CFO of the company, sold 3,700 shares for $1.95 each. As a result, the insider received 7,215 and left with 53,143 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GLYC now has a Market Capitalization of 190.13M and an Enterprise Value of 149.14M. For the stock, the TTM Price-to-Sale (P/S) ratio is 17820.43 while its Price-to-Book (P/B) ratio in mrq is 4.63. Its current Enterprise Value per Revenue stands at 14.91k whereas that against EBITDA is -3.81.
Stock Price History:
The Beta on a monthly basis for GLYC is 2.19, which has changed by 118.11% over the last 52 weeks, in comparison to a change of 26.95% over the same period for the S&P500. Over the past 52 weeks, GLYC has reached a high of $3.53, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is 2.9890, while the 200-Day Moving Average is calculated to be 2.0324.
Shares Statistics:
It appears that GLYC traded 360.72K shares on average per day over the past three months and 469.97k shares per day over the past ten days. A total of 64.39M shares are outstanding, with a floating share count of 58.37M. Insiders hold about 9.44% of the company’s shares, while institutions hold 47.24% stake in the company. Shares short for GLYC as of Feb 29, 2024 were 1.56M with a Short Ratio of 4.13, compared to 997.93k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.42% and a Short% of Float of 3.48%.
Earnings Estimates
As of right now, 3 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.15 for the current quarter, with a high estimate of -$0.14 and a low estimate of -$0.15, while EPS last year was -$0.17. The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.11 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.56 and -$0.68 for the fiscal current year, implying an average EPS of -$0.61. EPS for the following year is -$0.45, with 4 analysts recommending between $0.08 and -$0.91.
